Cargando…

Explaining COVID-19 postvaccination-related immune thrombotic thrombocytopenia: a hypothesis-generating in-silico approach

Cases that experienced COVID-19 postvaccination-related thrombosis have been reported after the first dose of ChAdOx1 nCov-19 (Vaxzevria, AstraZeneca) or Ad26.COV2.S (Johnson & Johnson/Janssen) vaccine. These rare thrombotic events were observed within the expected vaccine-induced seroconversion...

Descripción completa

Detalles Bibliográficos
Autor principal:	Konstantinou, George N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2022
Materias:	Coronavirus – Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9196821/ https://www.ncbi.nlm.nih.gov/pubmed/35412949 http://dx.doi.org/10.1080/21645515.2022.2050654

Ejemplares similares

Recognizing, managing and reporting vaccine-induced immune thrombotic thrombocytopenia
por: Sholzberg, Michelle, et al.
Publicado: (2021)

COVID-19 Vaccines and Hyperglycemia—Is There a Need for Postvaccination Surveillance?
por: Samuel, Samson Mathews, et al.
Publicado: (2022)

Using a “systems therapeutic for physiological renormalization” approach to vaccine development. Covid-19 as an example
por: Maguire, Greg
Publicado: (2022)

Postvaccine Myocarditis: A Risk Worth the Reward?
por: Raman, Betty, et al.
Publicado: (2022)

Clinical characteristics in immune thrombocytopenia patients after COVID-19 vaccination
por: Feng, Yimei, et al.
Publicado: (2022)

Enhanced replication fitness of MERS-CoV clade B over clade A strains in camelids explains the dominance of clade B strains in the Arabian Peninsula
por: Te, Nigeer, et al.
Publicado: (2021)

The impact of health literacy on COVID-19 immunization
por: Sayar, Merve Sefa, et al.
Publicado: (2023)

COVID-19: imbalanced cell-mediated immune response drives to immunopathology
por: Wang, Jun, et al.
Publicado: (2022)

The modulatory action of C-Vx substance on the immune system in COVID-19
por: Tahrali, Ilhan, et al.
Publicado: (2022)

Safety of COVID-19 vaccines in subjects with solid tumor cancers receiving immune checkpoint inhibitors
por: Gilbert, Danielle, et al.
Publicado: (2023)

Heterologous booster with inhaled adenovirus vector COVID-19 vaccine generated more neutralizing antibodies against different SARS-CoV-2 variants
por: Zhong, Jiaying, et al.
Publicado: (2022)

Booster vaccination is required to elicit and maintain COVID-19 vaccine-induced immunity in SIV-infected macaques
por: Li, Pingchao, et al.
Publicado: (2023)

Consideration of COVID-19 beyond the human-centred approach of prevention and control: the ONE-HEALTH perspective
por: Li, Qin, et al.
Publicado: (2022)

Hypothesis to explain the severe form of COVID-19 in Northern Italy
por: Cegolon, Luca, et al.
Publicado: (2020)

COVID-19 breakthrough infections and humoral immune response among BNT162b2 vaccinated healthcare workers in Malaysia
por: Yang, Su Lan, et al.
Publicado: (2022)

Mouse study of combined DNA/protein COVID-19 vaccine to boost high levels of antibody and cell mediated immune responses
por: He, Qian, et al.
Publicado: (2022)

Status of COVID-19 vaccination around South Asia
por: Hayat, Mahnoor, et al.
Publicado: (2022)

Immunomodulatory and therapeutic implications of vitamin D in the management of COVID-19
por: Dhawan, Manish, et al.
Publicado: (2022)

COVID-19 vaccine hesitancy: misinformation and perceptions of vaccine safety
por: Kricorian, Katherine, et al.
Publicado: (2021)

Homologous or heterologous immunization regimens against SARS-CoV-2 after two doses of inactivated COVID-19 vaccine: Comment
por: Mungmunpuntipantip, Rujitika, et al.
Publicado: (2023)

Resolving sex and gender bias in COVID-19 vaccines R&D and beyond
por: Vijayasingham, Lavanya, et al.
Publicado: (2022)

Low coverage of COVID-19 vaccines in Africa: current evidence and the way forward
por: Lawal, Lukman, et al.
Publicado: (2022)

Digital tools, multidisciplinarity and innovation for communicating vaccine safety in the COVID-19 era
por: Gesualdo, Francesco, et al.
Publicado: (2021)

The impact of COVID-19 pandemic on rabies post-exposure prophylaxis services in Asia
por: Gongal, Gyanendra, et al.
Publicado: (2022)

Three doses of an inactivation-based COVID-19 vaccine induces cross-neutralizing immunity against the SARS CoV-2 Omicron variant
por: Yu, Xiaoling, et al.
Publicado: (2022)

A 1-year longitudinal study on COVID-19 convalescents reveals persistence of anti-SARS-CoV-2 humoral and cellular immunity
por: Li, Yang, et al.
Publicado: (2022)

Hybrid immunity and protection against infection during the Omicron wave in Malta
por: Cauchi, John Paul, et al.
Publicado: (2023)

Potential changes in vaccine access and policy landscape in Thailand post COVID-19 pandemic
por: Kategeaw, Warittakorn, et al.
Publicado: (2022)

Single cell characteristics of patients with vaccine-related adverse reactions following inactivated COVID-19 vaccination
por: Jiang, Manling, et al.
Publicado: (2023)

Victorian Specialist Immunisation Services (VicSIS) – bolstering adult clinics for COVID-19 vaccines
por: Gordon, Sally F., et al.
Publicado: (2022)

Impact of a focus education in Zoom on COVID-19 vaccine hesitancy in Hong Kong parents of the preschoolers
por: Wong, Wilfred Hing-sang, et al.
Publicado: (2022)

COVID-19 vaccine demand protest might have increased vaccine acceptance and uptake in South Africa
por: Mavundza, Edison Johannes, et al.
Publicado: (2022)

The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron
por: Zhang, Li, et al.
Publicado: (2021)

ACE2 decoy receptor generated by high-throughput saturation mutagenesis efficiently neutralizes SARS-CoV-2 and its prevalent variants
por: Wang, Bolun, et al.
Publicado: (2022)

Addressing an urgent global public health need: Strategies to recover routine vaccination during the COVID-19 pandemic
por: Larson, Anna, et al.
Publicado: (2021)

Online mis/disinformation and vaccine hesitancy in the era of COVID-19: Why we need an eHealth literacy revolution
por: Dib, Fadia, et al.
Publicado: (2021)

Combining intramuscular and intranasal homologous prime-boost with a chimpanzee adenovirus-based COVID-19 vaccine elicits potent humoral and cellular immune responses in mice
por: Li, Xingxing, et al.
Publicado: (2022)

The role of SARS-CoV-2 nucleocapsid protein in antiviral immunity and vaccine development
por: Yu, Haiyun, et al.
Publicado: (2023)

Changes in SARS-CoV-2 seroprevalence and population immunity in Finland, 2020–2022
por: Solastie, Anna, et al.
Publicado: (2023)

Strategies to tackle SARS-CoV-2 Mu, a newly classified variant of interest likely to resist currently available COVID-19 vaccines
por: Hossain, Md. Jamal, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3v8n659nvnn0ppd4u7tevnt35u